Coordinating data monitoring committees and adaptive clinical trial designs

Research output: Contribution to journalArticle

Abstract

There is a growing interest in employing adaptive clinical trial designs in drug development. Adaptation is usually based on accumulative efficacy data alone. This article examines issues that can arise when an independent data monitoring committee must interface their safety concerns when adaptive changes based on efficacy are taking place. Several types of adaptive changes are examined and the degree of complexity that safety concerns might introduce is discussed. Recommendations are made for sponsor-data monitoring committee communications when the latter has safety concerns that make a particular kind of adaptation inadvisable. Recommendations are made for making adaptive change decisions, minimizing bias, and training DMC and sponsor staff for participation in adaptive design trials.

Original languageEnglish (US)
Pages (from-to)297-301
Number of pages5
JournalDrug Information Journal
Volume42
Issue number4
StatePublished - Sep 10 2008

Fingerprint

Clinical Trials Data Monitoring Committees
Safety
Monitoring
Drug Design
Clinical Trials
Communication
Pharmaceutical Preparations

Keywords

  • Adaptive design
  • Data analysis center
  • Data monitoring committee
  • Internal safety review committee

ASJC Scopus subject areas

  • Pharmacology (nursing)
  • Drug guides
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

Coordinating data monitoring committees and adaptive clinical trial designs. / Herson, Jay.

In: Drug Information Journal, Vol. 42, No. 4, 10.09.2008, p. 297-301.

Research output: Contribution to journalArticle

@article{297e915610dd4d6d87cebd6539f79037,
title = "Coordinating data monitoring committees and adaptive clinical trial designs",
abstract = "There is a growing interest in employing adaptive clinical trial designs in drug development. Adaptation is usually based on accumulative efficacy data alone. This article examines issues that can arise when an independent data monitoring committee must interface their safety concerns when adaptive changes based on efficacy are taking place. Several types of adaptive changes are examined and the degree of complexity that safety concerns might introduce is discussed. Recommendations are made for sponsor-data monitoring committee communications when the latter has safety concerns that make a particular kind of adaptation inadvisable. Recommendations are made for making adaptive change decisions, minimizing bias, and training DMC and sponsor staff for participation in adaptive design trials.",
keywords = "Adaptive design, Data analysis center, Data monitoring committee, Internal safety review committee",
author = "Jay Herson",
year = "2008",
month = "9",
day = "10",
language = "English (US)",
volume = "42",
pages = "297--301",
journal = "Drug Information Journal",
issn = "0092-8615",
publisher = "Drug Information Association",
number = "4",

}

TY - JOUR

T1 - Coordinating data monitoring committees and adaptive clinical trial designs

AU - Herson, Jay

PY - 2008/9/10

Y1 - 2008/9/10

N2 - There is a growing interest in employing adaptive clinical trial designs in drug development. Adaptation is usually based on accumulative efficacy data alone. This article examines issues that can arise when an independent data monitoring committee must interface their safety concerns when adaptive changes based on efficacy are taking place. Several types of adaptive changes are examined and the degree of complexity that safety concerns might introduce is discussed. Recommendations are made for sponsor-data monitoring committee communications when the latter has safety concerns that make a particular kind of adaptation inadvisable. Recommendations are made for making adaptive change decisions, minimizing bias, and training DMC and sponsor staff for participation in adaptive design trials.

AB - There is a growing interest in employing adaptive clinical trial designs in drug development. Adaptation is usually based on accumulative efficacy data alone. This article examines issues that can arise when an independent data monitoring committee must interface their safety concerns when adaptive changes based on efficacy are taking place. Several types of adaptive changes are examined and the degree of complexity that safety concerns might introduce is discussed. Recommendations are made for sponsor-data monitoring committee communications when the latter has safety concerns that make a particular kind of adaptation inadvisable. Recommendations are made for making adaptive change decisions, minimizing bias, and training DMC and sponsor staff for participation in adaptive design trials.

KW - Adaptive design

KW - Data analysis center

KW - Data monitoring committee

KW - Internal safety review committee

UR - http://www.scopus.com/inward/record.url?scp=51049098442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51049098442&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:51049098442

VL - 42

SP - 297

EP - 301

JO - Drug Information Journal

JF - Drug Information Journal

SN - 0092-8615

IS - 4

ER -